Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial,The Lancet Oncology

当前位置： X-MOL 学术 › Lancet Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-08-09 , DOI: 10.1016/s1470-2045(24)00320-6
Pierre Vera ₁ , Sébastien Thureau ₂ , Florence Le Tinier ₃ , Philippe Chaumet-Riffaud ₄ , Sébastien Hapdey ₁ , Hélène Kolesnikov-Gauthier ₅ , Etienne Martin ₆ , Alina Berriolo-Riedinger ₇ , Nicolas Pourel ₈ , Jean Marc Broglia ₉ , Pierre Boissellier ₁₀ , Sophie Guillemard ₁₁ , Naji Salem ₁₂ , Isabelle Brenot-Rossi ₁₃ , Cécile Le Péchoux ₁₄ , Céline Berthold ₁₄ , Etienne Giroux-Leprieur ₁₅ , Damien Moreau ₁₆ , Sophie Guillerm ₁₇ , Khadija Benali ₁₈ , Laurent Tessonnier ₁₉ , Clarisse Audigier-Valette ₂₀ , Delphine Lerouge ₂₁ , Elske Quak ₂₂ , Carole Massabeau ₂₃ , Frédéric Courbon ₂₄ , Patricia Moisson ₂₅ , Anne Larrouy ₂₆ , Romain Modzelewski ₁ , Pierrick Gouel ₁ , Nadia Ghazzar ₂₇ , Alexandra Langlais ₂₈ , Elodie Amour ₂₈ , Gérard Zalcman ₂₉ , Philippe Giraud ₁₆

Affiliation

Nuclear Medicine Department and QuantIF LITIS (EA4108), Centre Henri Becquerel, Rouen, France.
Radiotherapy Department and QuantIF LITIS (EA4108), Centre Henri Becquerel, Rouen, France.
Radiotherapy Department, Centre Oscar Lambret, Lille, France.
Clinical Research Department, Hôpital National des 15-20, Paris, France.
Nuclear Medicine Department, Centre Oscar Lambret, Lille, France.
Radiotherapy Department, Centre Georges-François Leclerc, Dijon, France.
Nuclear Medicine, Centre Georges-François Leclerc, Dijon, France.
Unité Fonctionnelle Onco-Thoracique, Institut du Cancer, Avignon, France.
Nuclear Medicine Deparment, Institut Sainte-Catherine, Avignon, France.
Radiotherapy Department, Institut du Cancer de Montpellier, Montpellier, France.
Nuclear Medicine Department, Institut du Cancer de Montpellier, Montpellier, France.
Radiotherapy Department, Institut Paoli-Calmettes, Marseille, France.
Nuclear Medicine Department, Institut Paoli-Calmettes, Marseille, France.
Radiation Oncology Department, Gustave Roussy, Villejuif, France.
University Paris-Saclay, Department of Respiratory Diseases and Thoracic Oncology, Assistance Publique-Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne-Billancourt, France.
Oncology Radiotherapy Department, Paris Cité University, European Hospital Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
Department of Radiation Therapy, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
Nuclear Medicine Department, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris Nord, Paris, France.
Nuclear Medicine Department, Centre Intercommunal Sainte-Musse de Toulon-La Seyne-sur-mer, Toulon, France.
Pneumology Department, Centre Intercommunal Sainte-Musse de Toulon-La Seyne-sur-mer, Toulon, France.
Radiotherapy Department, Centre Francois Baclesse, Caen, France.
Nuclear Medicine Department, Centre Francois Baclesse, Caen, France.
Radiotherapy Department, Institut Claudius Regaud - Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
Nuclear Medicine Department, Institut Claudius Regaud - Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
Radiotherapy Department, Hopital René Huguenin - Institut Curie, Saint-Cloud, France.
Radiotherapy Department, Centre de Cancerologie Paris Nord, Sarcelles, France.
Nuclear Medicine Department, Paris Cité University, European Hospital Georges-Pompidou - Assistance Publique-Hôpitaux de Paris Centre, Paris, France.
Clinical Research Unit, Intergroupe Francophone de Cancérologie Thoracique, Paris, France.
Université Paris Cité, Thoracic Oncology Department, Centre d'Investigation Clinique Institut National de la Santé et de la Recherche Médicale 1425, Hôpital Bichat-Claude Bernard, Institut du Cancer - Assistance Publique-Hôpitaux de Paris Nord, Paris, France.

Thoracic radiation intensification is debated in patients with stage III non-small-cell lung cancer (NSCLC). We aimed to assess the activity and safety of a boost radiotherapy dose up to 74 Gy in a functional sub-volume given according to on-treatment [18F]fluorodeoxyglucose ([18F]FDG)-PET results.

中文翻译：

根据 [18F]FDG-PET 在 42 Gy 时的肿瘤残余摄取（RTEP7–IFCT-1402），对 III 期非小细胞肺癌患者进行适应性放疗（高达 74 Gy）或标准放疗（66 Gy）：一项多中心、随机、对照的 2 期试验

III 期非小细胞肺癌（NSCLC）患者的胸部放疗增强存在争议。我们旨在根据治疗中的 [18F]氟脱氧葡萄糖（[18F]FDG）-PET 结果，在功能子体积中评估高达 74 Gy 的加强放疗剂量的活性和安全性。

更新日期：2024-08-09

点击分享查看原文

点击收藏

阅读更多本刊新发论文